Ad spending for obesity, diabetes drugs is soaring this year, as drugmakers shell out nearly $500 million

The data demonstrates the rush by companies to capture new customers after months of hype around Novo Nordisk's Ozempic and Wegovy. 

from Health and Science https://ift.tt/9ms5A7D
https://ift.tt/UsBcmgF
https://ift.tt/ZM2itxu